Recombinant Human EPOR /Erythropoietin Receptor
- Known as:
- Recombinant Human EPOR /Erythropoietin Receptor
- Catalog number:
- ep-869
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Proxinobio
- Gene target:
- Recombinant Human EPOR /Erythropoietin Receptor
Related genes to: Recombinant Human EPOR /Erythropoietin Receptor
- Gene:
- EPOR NIH gene
- Name:
- erythropoietin receptor
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 19p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-05-14
- Date modifiied:
- 2017-07-12
Related products to: Recombinant Human EPOR /Erythropoietin Receptor
Related articles to: Recombinant Human EPOR /Erythropoietin Receptor
- This study aimed to investigate erythropoietin receptor (EPOR) expression in human AKI and to examine its association with histopathological severity and clinical parameters. - Source: PubMed
Publication date: 2026/04/07
Xie KunZhou GangLi MengjinFu LiliWang RongZhang LimingMei ChanglinXue ChengXu Daoliang - This study aims to elucidate the pharmacological basis and antidepressant mechanisms of a combined extract from Eucommia ulmoides Oliv. And Gastrodia elata Bl. (Eucommia-Gastrodia extract), employing an integrated strategy that combines UHPLC-QTOF-MS analysis, network pharmacology, molecular docking, and in vivo validation. - Source: PubMed
Publication date: 2026/03/31
Xue LanqiongPan ZhuoyueLiu YaoGan QiulingLiu DongLiu Dingding - The emergence of tumor cell resistance is one of the major issues in current oncology practice. It reduces the effectiveness of therapy and worsens cancer patients' prognoses. However, it confirms a wide range of molecular interactions as well as the complexity of the human organism. Our previous research confirmed the functionality of the erythropoietin receptor (EPOR) in ovarian and breast cancer cells, as well as its relationship to these cells' sensitivity to specific therapies. The current study demonstrates that EPOR overexpression in human ovarian adenocarcinoma cells A2780 is directly linked to paclitaxel resistance. Furthermore, EPOR overexpression results in morphological changes that vary according to the pattern of EPOR isotypes expressed. In this regard, the most interesting result appears to be the change in the shape of the T clone, which has a tendency to form spheroidal structures. In addition, functional enrichment analysis demonstrated that EPOR-associated differentially expressed genes are involved in several biological and cell processes. Indeed, a T clone with a single 68 kDa EPOR isotype demonstrates significant resistance to paclitaxel therapy and is associated with the upregulation of tubulin beta 6. - Source: PubMed
Publication date: 2026/02/16
Harvanik PavolDanková KristínaSolárová ZuzanaŠemeláková MartinaBhide MangeshSolár Peter - The erythropoietin receptor (EPOR) is a single-pass transmembrane protein that homo-dimerizes upon binding with its renal ligand erythropoietin (EPO) to trigger downstream signaling. Its extracellular ectodomain mediates ligand binding. Therefore, a fusion protein of the EPOR ectodomain can be useful for various in vitro assays, such as a binding assay with an EPO-like peptide, if overexpressed in Escherichia coli (E.coli). In this study, we hypothesized that fusion proteins of the EPOR ectodomain with mCitrine or mTFP1, expressed in bacteria, could enable in vitro Förster resonance energy transfer experiments. Two fusion proteins, EPOR-mCitrine and EPOR-mTFP1, were overexpressed in E. coli but obtained as inclusion bodies. Urea solubilization and stepwise dialysis yielded soluble fusion proteins. Circular dichroism spectroscopy revealed that EPOR-mCitrine had greater secondary structure content than EPOR-mTFP1. When combined with recombinant human EPO, the hydrodynamic radius of EPOR-mCitrine changed, as measured using dynamic light scattering, confirming binding. This interaction was further validated using isothermal titration calorimetry. We propose that bacterially produced EPOR-mCitrine is a useful in vitro tool for measuring EPO binding. - Source: PubMed
Publication date: 2026/03/27
Kang EunhoAshim JanbolatJi SanghoHan Min AeYu WookyungKim Sung JaeHong EunmiMoon CheilLee Chang-Hun - Oxaliplatin, a widely used chemotherapeutic agent, is associated with hematologic toxicities such as anemia, leukopenia, and thrombocytopenia. Despite their clinical relevance, the molecular mechanisms underlying lineage-specific bone marrow suppression remain poorly understood. - Source: PubMed
Publication date: 2026/02/16
Sudlow Leland CDu JunweiShahverdi KianaZhou HaiyingBerezin Mikhail Y